Brainstorm Cell Therapeutics Inc. (BCLI) SEC Filing 8-K Material Event for the period ending Monday, April 26, 2021

Brainstorm Cell Therapeutics Inc.

CIK: 1137883 Ticker: BCLI


Exhibit 99.1


BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update


Positive Phase 2 data demonstrate the potential of NurOwn® as a treatment for progressive MS


Regulatory strategy progressing to advance NurOwn’s approval in ALS


Conference call and webcast at 8:00 a.m. Eastern Time today


NEW YORK, April 26, 2021 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2021 and provided a corporate update.


“In the first quarter we were excited to announce positive top line data from our Phase 2 trial evaluating NurOwn® as a treatment for progressive multiple sclerosis (MS). These data expand the body of evidence supporting the NurOwn® technology platform across neurodegenerative diseases,” said Chaim Lebovits, Chief Executive Officer of BrainStorm. “In our ALS program, we intend to submit a manuscript for peer review shortly and are delivering scientific presentations. We are currently in active discussions with various experts including principal investigators, ALS physicians, statisticians, regulatory advisors as well as patient advocacy groups, in addition to potential strategic partners. Based on all feedback received, we will assess the best path forward to enable patients access to NurOwn including FDA BLA submission and/or other regulatory and business options.”


First Quarter 2021 Corporate Highlights

·Announced positive top-line data from the open label Phase 2 trial evaluating NurOwn® as a treatment for progressive multiple sclerosis (MS). The trial achieved the primary endpoint of safety and demonstrated clinically meaningful improvements in multiple endpoints.
oConsistent improvement across all functional measures were observed, in comparison to the matched clinical cohort from the Comprehensive Longitudinal Investigations in MS at the Brigham & Woman's Hospital (CLIMB Study).
oPre-specified responder analysis demonstrated consistent improvements in functional measures including walking, vision and cognition. These improvements were not seen in any of the matched CLIMB patients.
oConsistent increases in delivered neurotrophic factors and a reduction across key inflammatory biomarkers were observed.
·Following FDA feedback on the Phase 3 NurOwn ALS clinical data, and enacting FDA advice, we have made great progress in the important steps needed to develop and then act on our regulatory strategy. These include submission of a manuscript for a peer-reviewed publication of NurOwn’s Phase 3 clinical trial results and conducting ongoing consultations with key ALS stakeholders in the U.S. and other jurisdictions confirming the strength of the data and providing feedback and valuable guidance on next steps.
·Published data from a preclinical study showing that intrathecal administration of NurOwn derived exosomes significantly improved lung function and histology in a mouse model of acute respiratory distress syndrome (ARDS), a type of respiratory failure frequently associated with COVID-19. The study, entitled, "MSC-NTF (NurOwn) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model," was published in the peer-reviewed journal Stem Cell and Research Therapy.


Presented at the following investor conferences:

·10th Annual SVB Leerink Global Healthcare Conference


Cash and Liquidity as of March 31, 2021


Total available funding as of March 31, 2021, which includes cash, cash equivalents and short-term bank deposits of approximately $40.0 million, an untapped ATM capacity of approximately $16.0 million, as well as remaining non-dilutive funding from grants, amounts to approximately $57.0 million.





Financial Results for the Three Months Ended March 31, 2021


Cash, cash equivalents, and short-term bank deposits were approximately $40.0 million as of March 31, 2021, compared to approximately $42.0 million on December 31, 2020.


Research and development expenses, net for the three months ended March 31, 2021 and 2020 were approximately $4.3 million and $5.9 million, respectively.


Excluding participation from IIA and CIRM under the grants and proceeds received under the hospital exemption regulatory pathway, research and development expenses decreased by approximately $2.3 million from $7.1 million in the first quarter of 2020 to $4.8 million in the first quarter of 2021.


General and administrative expenses for the three months ended March 31, 2021 and 2020 were approximately $2.6 million and $2.4 million, respectively.


Net loss for the three months ended March 31, 2021 was approximately $6.6 million, as compared to a net loss of approximately $8.1 million for the three months ended March 31, 2020.


Net loss per share for the three months ended March 31, 2021 and 2020 was $0.19 and $0.32, respectively.


Conference Call & Webcast


Monday, April 26, 2021 at 8:00 a.m. Eastern Time

From the U.S.: 877-407-9205
International: 201-689-8054 
Webcast URL:


Replays, available through May 10, 2021

From the U.S.: 877-481-4010
International: 919-882-2331 
Replay Passcode: 40513


About NurOwn®

The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.


About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).


For more information, visit the company's website at





Safe-Harbor Statement 

Statements in this announcement other than historical data and information, including statements regarding future NurOwn® manufacturing and clinical development plans, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, the prospects for regulatory approval of BrainStorm's NurOwn® treatment candidate, the initiation, completion, and success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture, or to use third parties to manufacture, and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.


Investor Relations:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Phone: +1 646-465-1138


Paul Tyahla
Phone: + 1.973.713.3768







U.S. dollars in thousands

(Except share data)


   March 31,   December 31, 
   2021   2020 
   U.S. $ in thousands 
Current Assets:          
Cash and cash equivalents  $35,933   $37,829 
Short-term deposit (Note 4)   4,114    4,107 
Other accounts receivable   255    304 
Prepaid expenses and other current assets (Note 5)   728    1,002 
Total current assets   41,030    43,242 
Long-Term Assets:          
Prepaid expenses and other long-term assets   27    26 
Operating lease right of use asset (Note 6)   6,426    6,872 
Property and Equipment, Net   1,088    1,119 
Total Long-Term Assets   7,541    8,017 
Total assets  $48,571   $51,259 
Current Liabilities:          
Accounts payable  $2,552   $5,417 
Accrued expenses   1,748    1,261 
Operating lease liability (Note 6)   2,299    2,655 
Other accounts payable   1,592    1,900 
Total current liabilities   8,191    11,233 
Long-Term Liabilities:          
Operating lease liability (Note 6)   4,179    4,562 
Total long-term liabilities   4,179    4,562 
Total liabilities  $12,370   $15,795 
Stockholders’ Equity:          
Stock capital: (Note 7)   12    12 
Common Stock of $0.00005 par value - Authorized: 100,000,000 shares at March 31, 2021 and December 31, 2020 respectively; Issued and outstanding: 36,318,561 and 35,159,977 shares at March 31, 2021 and December 31, 2020 respectively.          
Additional paid-in-capital   192,054    184,655 
Treasury stocks   (116)   (116)
Accumulated deficit   (155,749)   (149,087)
Total stockholders’ equity   36,201    35,464 
Total liabilities and stockholders’ equity  $48,571   $51,259 







U.S. dollars in thousands

(Except share data)


   Three months ended 
   March 31, 
   2021   2020 
Operating expenses:          
Research and development, net (Note 8)  $4,341   $5,948 
General and administrative   2,588    2,360 
Operating loss   (6,929)   (8,308)
Financial income, net   267    194 
Net loss  $(6,662)  $(8,114)
Basic and diluted net loss per share from continuing operations  $(0.19)  $(0.32)
Weighted average number of shares outstanding used in computing basic and diluted net loss per share   35,791,309    28,423,837 



0001137883 false 0001137883 2021-02-26 2021-02-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 26, 2021


Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-36641   20-7273918
(State or other jurisdiction of
  (Commission File No.)   (IRS Employer Identification No.)


1325 Avenue of Americas, 28th Floor  
New York, NY 10019
(Address of principal executive offices) (Zip Code)


(201) 488-0460

(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.00005 par value BCLI

NASDAQ Stock Market LLC

(Nasdaq Capital Market)


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 2.02. Results of Operations and Financial Condition.


On April 26, 2021, Brainstorm Cell Therapeutics Inc. (the “Company”) issued a press release announcing its financial and operating results for the quarter ended March 31, 2021. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.


The Company will host a live conference call and webcast at 8:00 am ET on Monday, April 26, 2021 to discuss first quarter 2021 financial results and business progress. A live webcast of the conference call may be accessed by visiting the Investors & Media section of the Company’s website at


The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits




99.1   Press Release issued by the Company on April 26, 2021, furnished hereto.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document) 







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 26, 2021 By: /s/ Chaim Lebovits
    Chaim Lebovits
  Chief Executive Officer



View differences made from one to another to evaluate Brainstorm Cell Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Brainstorm Cell Therapeutics Inc..


Assess how Brainstorm Cell Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Brainstorm Cell Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Brainstorm Cell Therapeutics Inc. provided additional information to their SEC Filing as exhibits

Ticker: BCLI
CIK: 1137883
Form Type: 8-K Corporate News
Accession Number: 0001104659-21-054690
Submitted to the SEC: Mon Apr 26 2021 7:05:13 AM EST
Accepted by the SEC: Mon Apr 26 2021
Period: Monday, April 26, 2021
Industry: Biological Products No Disgnostic Substances
  1. Earnings Release
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: